Search for: "Astrazeneca LP"
Results 41 - 60
of 156
Sort by Relevance
|
Sort by Date
25 Oct 2013, 3:56 am
In the court’s view, this circumstantial evidence of a “pattern of antagonism” raised an inference of retaliation and was enough to support her Title VII claim (Brangman v AstraZeneca, LP). [read post]
19 Sep 2013, 9:53 am
The following post is exclusively the work of the Reed Smith side of the blog.Sometimes the smallest, least significant type of lawsuit can illustrate cracks in the edifice of the largest, most consequential litigation. [read post]
14 Aug 2013, 1:57 pm
We’ve already provided our readers with our list of the testimony (trial and deposition) of the seemingly ubiquitous plaintiff’s expert Dr. [read post]
31 Jul 2013, 4:58 am
Astrazeneca Pharms. [read post]
19 Jul 2013, 10:43 am
AstraZeneca Pharms. [read post]
4 Jun 2013, 11:22 am
Guinn v AstraZeneca Pharms. [read post]
14 May 2013, 6:18 pm
The lawsuits in the Nexium MDL claim that Nexium, created by manufacturer, AstraZeneca LP, causes side effects such as bone loss, which subsequently has resulted in fractures and similar symptoms. [read post]
24 Mar 2013, 8:01 pm
Watson Laboratories, Inc. - Florida et al. 3:13-cv-01669; filed March 19, 2013 in the District Court of New Jersey • Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; KBI Inc.; KBI-E Inc. [read post]
27 Feb 2013, 9:53 pm
LP v. [read post]
30 Nov 2012, 7:45 am
No. 10-915-LPS (D. [read post]
29 Nov 2012, 5:21 am
No. 10-915-LPS (D. [read post]
10 Sep 2012, 7:28 pm
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
17 Jul 2012, 4:40 am
See AstraZeneca LP v. [read post]
9 Jul 2012, 7:41 pm
Karst – In a decision that, unless appealed, marks the end of AstraZeneca Pharmaceuticals LP’s (“AstraZeneca’s”) battle with FDA over the approval of generic versions of the company’s blockbuster antipsychotic drug SEROQUEL (quetiapine fumarate) Tablets, the U.S. [read post]
15 Jun 2012, 12:19 pm
AstraZeneca LP, 2009 WL 1610575 at 8 (Del. [read post]
25 May 2012, 11:32 am
Judge Stark cited the Federal Circuit’s recent decision in AstraZeneca Pharmaceuticals LP v. [read post]
24 May 2012, 4:23 am
Astrazeneca LP, 2010 WL 3706584, at *6 (Del. [read post]
16 May 2012, 12:22 pm
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352, 1360-66 (11th Cir. 2011) (plaintiff had not pleaded recoverable economic injury); Polk v. [read post]
20 Apr 2012, 10:36 am
McGrath In its recent decision in AstraZeneca Pharmaceuticals LP v. [read post]
16 Apr 2012, 1:29 am
District Court are Motions for Summary Judgment filed by FDA and AstraZeneca Pharmaceuticals LP (here and here) concerning FDA’s approval of ANDAs for generic versions of SEROQUEL (quetiapine fumarate) Tablets and the Agency’s decision, discussed in a March 27, 2012 Letter Decision, concerning the scope and applicability of 3-year marketing exclusivity in that case. [read post]
